AI-Powered Platform Secures $6.5M To Simplify Medical Trials
Research Grid, an AI-driven company dedicated to automating clinical trial administration, has raised $6.5 million in seed funding to streamline trial workflows and reduce costly delays.
The funding round, led by Fuel Ventures and including backers like Ada Ventures, Morgan Stanley Inclusive Ventures Lab, and Arāya Ventures, will help Research Grid expand its engineering, R&D, and marketing efforts, with a focus on US and Asian markets.
This investment supports Research Grid’s mission to cut down on the labor-intensive administrative tasks that can hinder the speed and success of medical research.
Simplifying the Clinical Trial Lifecycle
Founded in London in 2020 by Dr. Amber Hill, Research Grid was built out of her firsthand frustration with repetitive admin tasks during her 14-year career in medical research.
The company’s two core products, Inclusive and TrialEngine, aim to automate trial recruitment, engagement, and data management processes.
The Inclusive platform tackles one of the toughest phases in clinical trials—recruiting diverse and representative patient samples.
Inclusive connects researchers with over 91,000 global communities spanning 2,050 medical conditions, making it easier and faster to reach diverse patients required by the FDA for inclusive studies.
“The back-office process is completely broken. When you look at the cumulative costs across the industry, the financial impact is astronomical,” Hill stated in a press release.
“Our goal is to remove admin bottlenecks, helping researchers focus on their core work.”
AI-Powered Trial Management Cuts Costs by 45%
TrialEngine, meanwhile, oversees trial operations by automating protocols, data entry, and reporting tasks.
Together, these products reduce admin burdens, leading to faster trial timelines and higher success rates, saving up to 45% on costs while improving patient engagement by 145%.
With this funding, Research Grid plans to scale its engineering and sales teams while investing in R&D for advanced AI solutions.
The company anticipates strong demand from pharmaceutical companies, contract research organizations, and research institutions.
Feature Image Credit: Amber Hill
